Manifestations and impact of the COVID-19 pandemic in neuroinflammatory diseases.


Journal

Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278

Informations de publication

Date de publication:
04 2021
Historique:
revised: 21 12 2020
received: 06 11 2020
accepted: 18 01 2021
pubmed: 23 2 2021
medline: 27 4 2021
entrez: 22 2 2021
Statut: ppublish

Résumé

To report initial results of a planned multicenter year-long prospective study examining the risk and impact of COVID-19 among persons with neuroinflammatory disorders (NID), particularly multiple sclerosis (MS). In April 2020, we deployed online questionnaires to individuals in their home environment to assess the prevalence and potential risk factors of suspected COVID-19 in persons with NID (PwNID) and change in their neurological care. Our cohort included 1115 participants (630 NID, 98% MS; 485 reference) as of 30 April 2020. 202 (18%) participants, residing in areas with high COVID-19 case prevalence, met the April 2020 CDC symptom criteria for suspected COVID-19, but only 4% of all participants received testing given testing shortages. Among all participants, those with suspected COVID-19 were younger, more racially diverse, and reported more depression and liver disease. PwNID had the same rate of suspected COVID-19 as the reference group. Early changes in disease management included telemedicine visits in 21% and treatment changes in 9% of PwNID. After adjusting for potential confounders, increasing neurological disability was associated with a greater likelihood of suspected COVID-19 (OR Our study of real-time, patient-reported experience during the COVID-19 pandemic complements physician-reported MS case registries which capture an excess of severe cases. Overall, PwNID seem to have a risk of suspected COVID-19 similar to the reference population.

Identifiants

pubmed: 33616290
doi: 10.1002/acn3.51314
pmc: PMC8013889
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

918-928

Subventions

Organisme : NINDS NIH HHS
ID : K23 NS107624
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS098023
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Informations de copyright

© 2021 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.

Références

Rehabil Nurs. 2019 Jan/Feb;44(1):52-59
pubmed: 30601432
Lancet Public Health. 2017 May 04;2(6):e260-e266
pubmed: 28626828
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Ann Neurol. 2016 Feb;79(2):178-89
pubmed: 26583565
Mult Scler. 2021 Jan;27(1):97-106
pubmed: 31933419
Neurology. 2014 Sep 2;83(10):929-37
pubmed: 25085638
Mult Scler Relat Disord. 2018 Feb;20:9-15
pubmed: 29274564
Mult Scler Relat Disord. 2019 May;30:98-103
pubmed: 30763908
Neurology. 2019 Apr 2;92(14):e1634-e1642
pubmed: 30867272
Health Qual Life Outcomes. 2012 Jun 18;10:70
pubmed: 22709981
Mult Scler Relat Disord. 2020 Apr;39:102073
pubmed: 32334820
Neurology. 2014 Jun 10;82(23):2112-9
pubmed: 24808019
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Neurology. 2020 Jun 2;94(22):949-952
pubmed: 32241953
Mult Scler. 2020 Nov;26(13):1797-1800
pubmed: 31668134
Lancet Neurol. 2020 Jun;19(6):481-482
pubmed: 32359409
Mult Scler Relat Disord. 2019 Nov;36:101258
pubmed: 31472419
PLoS One. 2013;8(3):e59707
pubmed: 23527256
Neurol Neuroimmunol Neuroinflamm. 2020 May 5;7(4):
pubmed: 32371550
Neurology. 2006 Aug 22;67(4):652-9
pubmed: 16870812
Mult Scler. 1999 Aug;5(4):251-9
pubmed: 10467384
Eur J Neurol. 2013 Aug;20(8):1153-60
pubmed: 23496086
Science. 2020 May 22;368(6493):860-868
pubmed: 32291278
J Clin Epidemiol. 2010 Nov;63(11):1179-94
pubmed: 20685078
Ann Intern Med. 2020 Jun 2;172(11):726-734
pubmed: 32282894
Nat Rev Neurol. 2017 Jun;13(6):375-382
pubmed: 28303911
Nat Med. 2020 Jul;26(7):1037-1040
pubmed: 32393804
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 02;5(6):e505
pubmed: 30775409
Am J Emerg Med. 2020 Jul;38(7):1519-1520
pubmed: 32305155
BMC Neurol. 2013 Apr 25;13:37
pubmed: 23617555
Mult Scler. 2018 Nov;24(13):1657-1664
pubmed: 30231004
Mult Scler. 2014 Jul;20(8):1102-11
pubmed: 24402035
Rehabil Psychol. 2014 May;59(2):220-229
pubmed: 24661030
Mult Scler Relat Disord. 2020 Jul;42:102120
pubmed: 32315980

Auteurs

Seth N Levin (SN)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
New York Presbyterian Hospital, New York, New York, USA.

Shruthi Venkatesh (S)

Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Katie E Nelson (KE)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.

Yi Li (Y)

Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Ines Aguerre (I)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.

Wen Zhu (W)

Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Karman Masown (K)

Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Kathryn T Rimmer (KT)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
New York Presbyterian Hospital, New York, New York, USA.

Claudiu I Diaconu (CI)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
New York Presbyterian Hospital, New York, New York, USA.

Kaho B Onomichi (KB)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.

Victoria M Leavitt (VM)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.

Libby L Levine (LL)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.

Rebecca Strauss-Farber (R)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.

Wendy S Vargas (WS)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
New York Presbyterian Hospital, New York, New York, USA.

Brenda Banwell (B)

Department of Neurology, Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, USA.

Amit Bar-Or (A)

Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Joseph R Berger (JR)

Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Andrew D Goodman (AD)

Department of Neurology, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, New York, USA.

Erin E Longbrake (EE)

Department of Neurology, Yale University, New Haven, Connecticut, USA.

Jiwon Oh (J)

Division of Neurology, Department of Medicine, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.

Bianca Weinstock-Guttman (B)

Department of Neurology, Jacobs Multiple Sclerosis Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, New York, USA.

Kiran T Thakur (KT)

New York Presbyterian Hospital, New York, New York, USA.

Keith R Edwards (KR)

The Multiple Sclerosis Center of Northeastern New York, Latham, New York, USA.

Claire S Riley (CS)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
New York Presbyterian Hospital, New York, New York, USA.

Zongqi Xia (Z)

Program in Translational Neuroimmunology, Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.

Philip L De Jager (PL)

Multiple Sclerosis Center and Center for Translational & Computational Neuroimmunology, Department of Neurology and Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Columbia University Irving Medical Center, New York, New York, USA.
New York Presbyterian Hospital, New York, New York, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH